28/03/2026 Biogen announced Phase 2 results for litifilimab for CLE Results from Sanofi’s Phase 3 studies in AD were presented AAD Alumis announced Phase 3 data for envudeucitinib for plaque psoriasis Incyte announced Phase 3 data for povorcitinib for HS Biogen announced Phase 2 results for litifilimab for CLE  ( Ref ) Biogen announced positive results from part A of its Phase2/3 AMETHYST/ NCT05531565  study, which evaluated litifilimab (BDCA2) for the treatment of patients w